AMPLIFY-7P Phase 2 Failure Forces Elicio Into High-Risk Pivot With Six-Month Runway

Elicio Therapeutics Reports Q2 2026 Financials and ELI-002 7P Clinical Updates

Elicio Therapeutics reported its second quarter 2026 financial results and provided key corporate and clinical updates. The company plans to initiate a Phase 1 combination study of ELI-002 7P with a RAS small molecule inhibitor, with or without an anti-PD-1 inhibitor, in metastatic pancreatic cancer in Q4 2026, following observations of multiple complete responses. While the Phase 2 AMPLIFY-7P trial for ELI-002 7P in adjuvant mKRAS-driven pancreatic cancer did not meet its primary endpoint, Elicio continues to evaluate subgroups to refine its Phase 3 strategy. An investigator-initiated Phase 1 neoadjuvant trial for ELI-002 7P plus chemotherapy and checkpoint inhibition, led by Memorial Sloan Kettering, has also been activated. Financially, a $15 million offering in July 2026 strengthened the balance sheet, extending the cash runway into Q1 2027.

• Advancing ELI-002 7P in Metastatic Pancreatic Cancer: Elicio Therapeutics is progressing ELI-002 7P with a planned Phase 1 combination study in metastatic pancreatic cancer, anticipated to start in Q4 2026. This decision follows encouraging clinical observations, including multiple complete responses, supporting the potential of their AMP platform when combined with RAS small molecule inhibitors and/or anti-PD-1 inhibitors.
• Phase 2 AMPLIFY-7P Trial Results and Future Strategy: The Phase 2 AMPLIFY-7P trial for ELI-002 7P in adjuvant mKRAS-driven pancreatic cancer did not achieve its primary endpoint. However, Elicio is continuing to analyze pre-specified subgroups, particularly the R0 resected population, to inform and refine the Phase 3 development strategy for ELI-002 7P in this indication.
• New Investigator-Initiated Neoadjuvant Study: An investigator-initiated Phase 1 trial has been activated to evaluate ELI-002 7P in combination with chemotherapy and an anti-PD-1 checkpoint inhibitor in neoadjuvant pancreatic cancer. This multi-center study is being led by Memorial Sloan Kettering Cancer Center and is supported by a strategic partnership between The Lustgarten Foundation and Break Through Cancer.

ELI-002 7P's Combination Potential in Metastatic Pancreatic Cancer

Recent clinical investigation in metastatic pancreatic ductal adenocarcinoma (PDAC) has increasingly focused on immunotherapy-based combinations to overcome the tumor's characteristically immunosuppressive microenvironment. Among the most clinically relevant approaches, the triple combination of toripalimab (a PD-1 inhibitor) with gemcitabine and nab-paclitaxel has demonstrated long-term partial response and acceptable tolerability in PD-L1-positive metastatic PDAC. A phase I study evaluating defactinib — a focal adhesion kinase inhibitor — combined with pembrolizumab and gemcitabine reported no dose-limiting toxicities, with a disease control rate of 80% and median overall survival of 7.8 months in the refractory cohort, and a disease control rate of 70% with median overall survival of 8.3 months in the maintenance cohort. Additionally, pembrolizumab combined with FOLFIRINOX has shown early signals of activity in the microsatellite instability-high (MSI-H) subpopulation, including decreased cancer burden and reduced FDG avidity on PET imaging.

Targeted therapy combinations represent another active area of development, stratified by molecular subtype. Olaparib is currently approved as maintenance monotherapy for germline BRCA-mutated advanced PDAC following platinum-based chemotherapy, with multiple PARP inhibitor trials ongoing — both as monotherapy and in combination — enrolling patients harboring DNA damage repair defects in genes including ATM, PALB2, and CHEK2. For KRAS wild-type PDAC, agents under investigation include ERBB inhibitors (afatinib, MCLA-128), TRK inhibitors (larotrectinib, entrectinib), the ALK/ROS inhibitor crizotinib, and BRAF/MEK inhibitors. Patients with the KRAS G12C mutation are being evaluated in trials with AMG510 and related agents.

Alongside these molecularly targeted and immunotherapeutic approaches, standard chemotherapy backbones remain the foundation of treatment for metastatic PDAC in routine practice. Modified FOLFIRINOX and nab-paclitaxel plus gemcitabine are the preferred regimens for patients with good performance status (ECOG 0–1 / KPS 70–100%), while gemcitabine with or without a second agent is recommended for those with ECOG PS 2–3. Emerging metabolic strategies are also being explored preclinically; a biomimetic "nutri-hijacker" approach combining biguanide-modified nanoparticulate albumin — which impairs glycolysis — with a flavonoid targeting glutaminolysis has demonstrated significant survival extension in PDAC-bearing mice when co-administered with hydroxychloroquine-based therapy, underscoring the breadth of mechanistic angles under active investigation.

Elicio's Strategic Pivot: Targeting mKRAS with Combination Immunotherapy

Pancreatic ductal adenocarcinoma (PDAC) remains one of oncology's most formidable challenges, characterized by its aggressive nature, high mortality, and a pervasive presence of KRAS mutations in over 90% of cases. Elicio Therapeutics' recent updates highlight both the promise and inherent complexities of tackling this disease with innovative immunotherapies. Their lymph node-targeting amphiphile vaccine, ELI-002 7P, represents a sophisticated approach designed to elicit potent, mKRAS-specific T cell responses. This mechanism has shown encouraging correlations with improved clinical outcomes in earlier studies, leveraging the critical role of lymph nodes in immune priming, a concept supported by research demonstrating enhanced immunogenicity through albumin-binding.

While the Phase 2 AMPLIFY-7P trial in adjuvant mKRAS-driven PDAC did not meet its primary endpoint, this outcome appears to be catalyzing a strategic evolution. The planned initiation of a Phase 1 combination study, pairing ELI-002 7P with a RAS small molecule inhibitor and potentially an anti-PD-1 agent, is a logical and necessary step. This approach acknowledges that single-agent immunotherapies often struggle against the immunosuppressive tumor microenvironment of KRAS-mutant PDAC, especially the aggressive KRAS G12D subtype, associated with decreased survival and reduced activated CD8 T cells. Combining immune activation with direct oncogenic pathway inhibition holds potential to overcome resistance and enhance therapeutic depth.

However, this path is not without considerations. The literature suggests achieving synergy between RAS inhibitors and anti-PD-1 agents can be challenging, with some studies showing no additive benefit in preclinical models. The inherent immunosuppression driven by KRAS mutations also poses a persistent hurdle. Elicio's continued evaluation of Phase 2 subgroups and activation of an investigator-initiated neoadjuvant study demonstrate commitment to understanding optimal platform application. With a strengthened balance sheet, the company is positioned to rigorously explore these combination strategies, aiming to transform the treatment paradigm for mKRAS-driven PDAC, moving beyond monotherapy towards a more comprehensive attack.